Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: Pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-κB

Annals of Clinical and Laboratory Science

Volumn 35, Issue 3, 2005, Pages 251-258

  Lun, Mingyue ^a   Zhang, Ping L ^a,b   Pellitteri, Phillip K ^b   Law, Amy ^b   Kennedy, Thomas L ^b   Brown, Robert E ^b  

^a WEIS CENTER FOR RESEARCH   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

Author keywords

NF B; siRNA; Squamous cell carcinoma; Velcade

Indexed keywords

BORTEZOMIB; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL GROWTH; CELL NUCLEUS; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG TARGETING; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION; VALIDATION PROCESS;

BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HUMANS; NF-KAPPA B; PYRAZINES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 23844442112     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Tamatani T, Azuma M, Aota K, Yamahita T, Bando T, Sato M. Enhanced IkappaB kinase activity responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells. Cancer Lett 2001;171:165-172.
2. Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, Mitchell JB, VanWaes C. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB. Head Neck 2000;22:748-759.
3. Zhang PL, Pellitteri PK, Law A, Gilroy PA, Wood GC, Kennedy TL, Blasick TM, Lun M, Schuerch C, Brown RE. Overexpression of phosphorylated nuclear factor-kappaB in tonsillar squamous cell carcinoma and high grade dysplasia is associated with poor prognosis. Mod Pathol 2005;18:924-932.
4. Dkhissi F, Raynal S, Lawrence DA. Altered complex formation between p21waf, p27kip and their partner G1 cyclins determines the stimulatory or inhibitory transforming growth factor-beta1 growth response in human fibroblasts. Int J Oncol 1999;14:905-910.
5. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-142.
6. Dixit V, Mak TW. NF-κB signaling: many roads lead to Madrid. Cell 2002;111:615-619.
7. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. P53 stabilization is decreased upon NF-kappaB activation: a role for NF-kappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503.
8. Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C, Van Waes C. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001; 7:435-442.
9. Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 2004;108:181-188.
10. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C. Constitutive activation of transcription factor NF-(kappa)B; AP-1 and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999;26:119-129.
11. Dong G, Loukinova E, Chen Z, Gangi L, Chanturita TI, Liu ET, Van Waes C. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res 2001;61:4797-4808.
12. Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. The bcl, NF-kappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol 2001;80:554-561.
13. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS. 4-1BB promotes the survival of CD8+T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002;169:4882-4888.
14. Bae JS, Jang MK, Hong S, An WG, Choi YH, Kim HD, Cheong J. Phosphorylation of NF-kappaB by calmodulin-dependent kinase IV activates anti-apoptotic gene expression. Biochem Biophys Res Commun 2003;305:1094-1098.
15. Kerstan A, Hunig T. Cutting edge: distinct TCR- and CD28- derived signals regulate CD 95L, Bcl-xL, and the survival of primary T-cells. J Immunol 2004;172:1341-1345.
16. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Non-steroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclinD1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-9258.
17. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 2004;111:679-692.
18. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-398.
19. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-2840.
20. Takada Y, Khuri FR, Aggarwal BB. Protein farnesyl-transferase inhibitor (SCH66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004;279:26287-26299.
21. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88-95.
22. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adam J, Sjak-Shie N, Vescio RA, Berenson JR. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-1144.
23. Lun M, Zhang PL, Siegelmann-Danieli, Blasick TM, Brown RE. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-NF-κB and p53 in breast cancer lines. Ann Clin Lab Sci 2005;35:15-24.
24. Renard P, Percherancier Y, Kroll M, Thomas D, Virelizier JL, Arenzana-Seisdedos F, Bachelerie F. Inducible NF-kappaB activation is permitted by simultaneous degradation of nuclear I-kappaB-alpha. J Biol Chem 2000; 275:15193-15199.
25. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R. Mechanisms of proteasome inhibitor, PS-341-induced G (2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9:1145-1154.
26. Yu J, Liu XW, Kim HR. Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promotor activity independent of p53. J Biol Chem 2003; 278:49582-49588.
27. Huo JX, Metz SA, Li GD. p53-independent induction of p21 (waf1/cip1) contributes to the activation of caspases in GTP-depletion induced apoptosis of insulin-secreting cells. Cell Death Differen 2004;11:99-109.
28. Reiss M, Brash DE, Munoz-Antonia T, Simon JA, Ziegler A, Vellucci VF, Zhou ZL. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncology Res 1992;4:349-357.
29. Carlos de Vicente J, Junquera Gutierrez LM, Zapatero AH, Fresno Forcelledo MF, Hernandez-Vallejo G, Lopez Arranz JS. Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastasis. Head Neck 2004;26:22-30.
30. Pukkila MJ, Kumpulainen EJ, Virtaniemi JA, Johansson RT, Halonen PM, Kellokoski JK, Kosunen AS, Nuutinen J, Kosma VM. Nuclear and cytoplasmic p53 expression in pharyngeal squamous cell carcinoma: prognostic implications. Head Neck 2002;24:784-791.
31. Schroeder CP, Yang P, Newman RA, Lotan R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biology Therapy 2004;3:847-852.
32. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventative agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21:2895-2900.
33. Holmes-McNary M, Baldwin AS Jr. Chemopreventative properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000;60:3477-3483.
34. Elattar TM, Virji AS. The effect of red wine and its components on growth and proliferation of human oral squamous cell carcinoma cells. Anticancer Res 1999; 19:5407-5414.
35. van Waes C, Lebowitz P, Conley B, Gius D, Adams J, Sausville E. NF-kappaB and proteasome inhibition in therapy of head and neck cancer. 5th International Conference on Head and Neck Cancer, Washington, DC, 11-15 August 2004 (Abstract 202).
36. Forte A, Cipollaro M, Cascino A, Galderisi U. Small interfering RNA's and antisense oligonucleotides for treatment of neurological diseases. Current Drug Targets 2005;6:21-29.